Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
SSY Group ( (HK:2005) ) has provided an update.
SSY Group Limited has received approval from China’s National Medical Products Administration for the production and registration of Levofloxacin Eye Drops and Compound Sodium Picosulfate Granules. These approvals expand the company’s ophthalmic and pharmaceutical offerings, potentially strengthening its market position and providing new treatment options for eye conditions and bowel cleansing procedures.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of various drug formulations. The company primarily offers ophthalmic preparations and other pharmaceutical products, with a market focus on enhancing its portfolio in these areas.
Average Trading Volume: 10,604,894
Technical Sentiment Signal: Hold
Current Market Cap: HK$9.15B
For an in-depth examination of 2005 stock, go to TipRanks’ Overview page.